Tiziana Life Sciences Ltd Total Assets

Latest as of March 2026: $11.49 Million USD

Tiziana Life Sciences Ltd total assets. Based on the latest financial reports, Tiziana Life Sciences Ltd (TLSA) holds total assets worth $11.49 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Tiziana Life Sciences Ltd market capitalisation for the company's overall valuation and market capitalisation.

Total Assets of Tiziana Life Sciences Ltd (1998–2025)

Total assets of Tiziana Life Sciences Ltd from 1998 to 2025. This chart illustrates how Tiziana Life Sciences Ltd's total assets have evolved over time, based on quarterly financial data. See TLSA share price today for real-time trading data and today's change.

Tiziana Life Sciences Ltd - Asset Composition Analysis

Tiziana Life Sciences Ltd Total Assets Breakdown (December 2025)

Tiziana Life Sciences Ltd total assets breakdown as of December 2025. Tiziana Life Sciences Ltd's total assets of $11.49 Million consist of 74.4% current assets and 25.6% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 34.9%
Accounts Receivable $4.26 Million 37.0%
Inventory $0.00 0.0%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $0.00 0.0%
Goodwill $0.00 0.0%

Asset Composition Trend (1998–2025)

This chart illustrates how Tiziana Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Tiziana Life Sciences Ltd to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Tiziana Life Sciences Ltd's current assets represent 74.4% of total assets in 2025, an increase from 28.2% in 1998.
  • Cash Position: Cash and equivalents constituted 34.9% of total assets in 2025, up from 21.1% in 1998.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 71.0% in 1998.
  • Asset Diversification: The largest asset category is accounts receivable at 37.0% of total assets.

Tiziana Life Sciences Ltd Competitors by Total Assets

Key competitors of Tiziana Life Sciences Ltd based on total assets are shown below.

Company Country Total Assets
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $11.57 Billion
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
USA $1.26 Billion
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
China CN¥13.56 Billion
Metsera, Inc. Common Stock
NASDAQ:MTSR
USA $639.66 Million
Xiamen Amoytop Biotech Co Ltd
SHG:688278
China CN¥3.21 Billion
SOLENO THERAPEUT. DL-001
F:6XC
Germany €563.83 Million
89bio Inc
NASDAQ:ETNB
USA $603.49 Million
LegoChem Biosciences Inc
KQ:141080
Korea ₩652.93 Billion

Tiziana Life Sciences Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.76 1.02 8.79
Quick Ratio 0.76 1.02 8.72
Cash Ratio 0.00 0.00 0.00
Working Capital $-2.66 Million $160.00K $62.09 Million

Tiziana Life Sciences Ltd - Advanced Valuation Insights

This section examines the relationship between Tiziana Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 19.23
Latest Market Cap to Assets Ratio 6.31
Asset Growth Rate (YoY) 1.9%
Total Assets $11.49 Million
Market Capitalization $72.52 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Tiziana Life Sciences Ltd's assets at a significant premium (6.31x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: Tiziana Life Sciences Ltd's assets grew by 1.9% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Tiziana Life Sciences Ltd (1998–2025)

The table below shows the annual total assets of Tiziana Life Sciences Ltd from 1998 to 2025.

Year Total Assets Change
2025-12-31 $11.49 Million +1.87%
2024-12-31 $11.28 Million -7.39%
2023-12-31 $12.18 Million -53.98%
2022-12-31 $26.48 Million -45.77%
2021-12-31 $48.83 Million -30.90%
2020-12-31 $70.66 Million +3807.96%
2019-12-31 $1.81 Million -66.85%
2018-12-31 $5.45 Million +197.84%
2017-12-31 $1.83 Million -63.75%
2016-12-31 $5.05 Million -45.39%
2015-12-31 $9.25 Million +276.02%
2014-12-31 $2.46 Million +1852.38%
2013-12-31 $126.00K +31.25%
2012-12-31 $96.00K -84.64%
2011-12-31 $625.00K -38.73%
2010-12-31 $1.02 Million -41.04%
2009-12-31 $1.73 Million -12.67%
2008-12-31 $1.98 Million -31.74%
2007-12-31 $2.90 Million -8.16%
2006-12-31 $3.16 Million -8.22%
2005-12-31 $3.44 Million -16.92%
2004-12-31 $4.14 Million +25.23%
2003-12-31 $3.31 Million +29.06%
2002-12-31 $2.56 Million -22.89%
2001-12-31 $3.33 Million -26.11%
2000-12-31 $4.50 Million +91.49%
1999-12-31 $2.35 Million -12.05%
1998-12-31 $2.67 Million --

About Tiziana Life Sciences Ltd

NASDAQ:TLSA USA Biotechnology
Market Cap
$72.52 Million
Market Cap Rank
#20361 Global
#4671 in USA
Share Price
$0.57
Change (1 day)
-6.65%
52-Week Range
$0.57 - $1.82
All Time High
$6.93
About

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more